• PULL signs Letter of Intent with Psyence Group to co-develop extraction techniques for production of psilocybin drug formulations
• Psyence is one of world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility
• PULL operates best-in-class processing infrastructure under Standard Processing License by Health Canada
• Near term milestones include Canada-based human clinical trials

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently signed a Letter of Intent with the Psyence Group to develop premium extraction techniques for the production of advanced psilocybin formulations that treat the mental health consequences of psychological trauma.

“We are excited about working with the deeply qualified science team at Psyence, one of only a handful of companies in the world operating a vertically integrated, federally licensed psychedelic mushroom facility,” said Pure Extracts CEO Ben Nikolaevsky (https://ibn.fm/iWj6b).

Led by an experienced team of global doctors and scientists, Psyence is one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility. The facility, located in Lesotho in Southern Africa, is dedicated to conducting cutting-edge research in neurology, palliative care, neuroscience and drug development. With its solid Canadian network of psychedelic mushroom research and development experts, Pure Extracts plans to leverage Psyence’s network in South Africa, Lesotho and Jamaica to rapidly develop natural psychedelics and novel drug delivery systems for patients across the world.

The companies plan to utilize their combined infrastructure and networks to attain near-term milestones. Pure Extracts operates a best-in-class production and processing facility under a Standard Processing License issued by Health Canada under the Cannabis Act, and the Psyence team has experience in structuring and running clinical trials. As part of their joint venture, both companies aim to conduct Canada-based human clinical trials as part of their near-term milestones.

“This partnership with Pure Extracts will facilitate the importation of our standardized psychedelic mushrooms into Canada, giving us the opportunity to further optimize extraction methods and produce advanced products needed for safe clinical research,” said Psyence Chief Scientific Officer Dr. Justin Grant. “Our companies share the vision of providing the highest quality and most innovative psilocybin products for Canada, as evidenced by our facilities being constructed to GMP standards, and our commitment to rigorous scientific and clinical research for the development of transformational treatments for mental health disorders, with a particular focus on oncology palliative care.”

Pure Extract’s state-of-the-art newly constructed processing facility is built to EU GMP standards with the aim of producing products for worldwide export where their sale and consumption are permitted. As new research reveals the effects of functional and medicinal psychedelic products (https://ibn.fm/pAkIw), Pure Extracts continues to make strides towards establishing a prominent position in the industry through its commitment to developing superior extracts for the rapidly growing plant-based wellness sector.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

 

• License essential to company’s plans to launch in one of world’s largest direct-selling markets
• SHRG honored to expand the Happy Co. into the country of South Korea
• Expansion into South Korea marks significant start to global expansion plans, sets the stage for growth in both U.S. and Asia

Sharing Services Global (OTCQB: SHRG) has obtained a direct-selling license in South Korea (https://ibn.fm/4AJvq); the license represents a key piece of the company’s plans to launch in that country, the third-largest, direct-selling market in the world. “We will be announcing additional products and services as this launch is planned in the near future, but for now, we are very pleased to share this exciting news,” said SHRG CEO John “JT” Thatch. Sharing Services’ strategic Asia Expansion Plan comes at an ideal time for the company, as SHRG just unveiled a new brand identity as the Happy Co. earlier this year. The rebranding features a look and design meant to help its partners and customers “recall happiness and reflect on the importance of family and community in their lives” (https://ibn.fm/zi3ic). Every element of the new brand identity has been deliberately chosen to create, strengthen and maintain the pleasant feelings that already represent the company through its unique blend of proprietary products. “The Happy Co. is not just a name; it is the best descriptor of our mission,” said Bo Short, CEO of SHRG subsidiaries Elevacity Holdings LLC and Elevacity International Holdings LLC. “It directly mirrors our values and purpose of sharing happiness through products and experiences that elevate lives. Our brand partners and our customers live this experience every day. This new branding is an important step as we begin our global expansion in 2021. It connects perfectly to our enhanced business platform and ever-growing ecosystem of products.” “We are honored to have the opportunity to expand the Happy Co. into the country of South Korea,” Short continued. “We are excited for our global family of brand partners and their ability to connect our business platform to entrepreneurs and customers in the great country of South Korea.” The expansion into South Korea “marks a significant start to our global expansion plans and will set the stage for growth both in the U.S. and in Asia simultaneously,” stated SHRG director Fai Chan. “We are glad to have a local Korean team that has tremendous experience both in South Korea and in the direct selling space to head up our expansion efforts in guiding the company to achieve greatness and success in the right way.” More details about the company’s plans to launch in South Korea will be forthcoming, as SHRG prepares pre-launch activities in the coming weeks. Sharing Services Global Corporation, formerly Sharing Services Inc., is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner
• XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards
• The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April
• XPhyto has just completed a rebranding effort that includes the launch of a new website
• The company expects to begin launching other bacteria and virus diagnostic products later this year

With confidence in the world’s mounting recovery from the COVID-19 pandemic growing this year, bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is stepping up its efforts to produce and ultimately commercialize next-generation diagnostic products and new active pharmaceutical ingredients, particularly in regard to the pandemic response. XPhyto has placed its first order for the company’s Covid-ID Lab product from its exclusive diagnostic development partner, Germany’s 3a-diagnostics GmbH, as announced in a Feb. 24 news release (https://ibn.fm/uBX94). The Covid-ID Lab is a rapid, point-of-care RT-PCR test system for COVID that the company expects to be useful for industry partners and licensees, as well as their respective government regulators, in safeguarding against the spread of the highly infectious and potentially fatal virus. The first product order from 3a was for 9,600 tests, which are packaged in 200 kits of 48 tests each, according to the company. Delivery is expected this month and XPhyto anticipates they will then undergo evaluation by the company’s partners and the appropriate government agencies for expected commencement of sales in Q2 2021. “We are pleased to report that all steps towards the launch of Covid-ID Lab remain on track within an ambitious timeline,” XPhyto CEO and Director Hugh Rogers stated in the news release. “Our experienced market launch team is working quickly to bring the product to market, as well as to establish licensing and distribution partnerships. We are confident that Covid-ID Lab, as a 25-minute PCR test with minimal technical and personnel requirements, will be a stand-out product in the COVID-19 test market.” In March, XPhyto received two critical regulatory approvals in Europe to open the door for sales of its rapid, point-of-care COVID testing solution. On March 10, the company announced approval for commercial production under internationally agreed-on ISO 13485 quality standards (https://ibn.fm/qZCXm). On March 18, the company further announced Covid-ID Lab’s approval for in vitro diagnostic device (CE-IVD) use (https://ibn.fm/PqsZI). On March 4, XPhyto announced completion of a corporate rebranding initiative that includes the launch of a new website. “The company is excited to introduce a fresh look at such a pivotal point in our business growth,” Rogers added (https://ibn.fm/A4hzB). XPhyto is on track to launch sales and distribution in Europe in April, and the company is also in talks with potential distribution and wholesale partners in the Middle East. XPhyto intends to continue its rapid, point-of-care product development to target other pandemic-potential illnesses, such as H1N1 (swine flu) and H5N1 (avian flu), as well as a variety of other bacterial and viral infectious diseases. New products under an expanding portfolio could be launched before the end of the year. XPhyto’s research and development operations are located in North America and Europe, but the company’s focus is the European market during these initial stages of product placement. For more information on XPhyto Therapeutics, visit the company’s newly designed website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Distribution of neurologists across the U.S. is uneven with 20 states experiencing neurology deserts
• Brain Scientific has developed tools that help providers in neurology deserts provide access to neurological care
• With explosion of telemedicine services and increased integration of advanced practice providers, neurologists’ shortage may improve

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is directly tackling the shortage of neurologists in the United States with cutting-edge technologies. By creating cost-efficient, disposable and portable EEGs, BRSF makes neurology care more accessible without putting excess strain on the already overextended neurologist labor pool.

Between 2001 and 2016, the American Academy of Neurology (“AAN”) reported that out-of-pocket costs shot up substantially for privately insured patients. In addition, the distribution of neurologists across the U.S. is uneven, with patients in rural areas less likely to receive care (https://ibn.fm/9sUYR). There are 20 states, according to the 2017 Alzheimer’s Association International Conference, classified as neurology deserts (https://ibn.fm/cGx2k). This term designates an area that has projected a chronic shortage of neurologists alongside a rise in dementia cases.

“In many places, people do not have easy access to specialists, for a variety of reasons. But you may not need a neurologist in every case,” said Beth Kallmyer, MSW, vice president of Constituent Services at the Alzheimer’s Association. “With the right training and tools, primary care physicians can effectively diagnose and treat Alzheimer’s disease. The Alzheimer’s Association is working to arm primary care physicians with the tools they need to manage an increased caseload, as well as care planning guidance.”

Brain Scientific has developed tools that provide primary care physicians in neurology deserts the ability to serve their patients and create specialized treatment plans that provide access to neurologists. Portable, clinical-grade, easy-to-use diagnostic devices are now in place to allow to run EEG tests withing a few minutes. The company is actively working on a secure, cloud-based and highly scalable infrastructure to transmit patient data between neurologists and patients as well as creating artificial intelligence assisted diagnostic analysis.

Currently, across the United States, there is significant disparity between who has access to neurology care and who does not. A MedPate Today article reported that the lowest density had a mean of 9.7 neurologists for every 100,000 Medicare beneficiaries while the highest had 43.1 neurologists for every 100,000 (https://ibn.fm/dGCud). While the number of conditions remained similar, the access to care did not. With the explosion of telemedicine services and an increased integration of advanced practice providers, neurologists’ shortage may just improve.

Through portable EEGs, teleneurology, on-demand data exchange and AI predictive biomarkers, Brain Scientific will create resources to narrow this wide gap. The company’s commercialized products were designed to disrupt the slow, expensive and cumbersome EEG market with easy-to-use, economical and disposable solutions. These devices are so easy to use that any medical professional can use them within minutes in any setting to run routine EEG studies.

Brain Scientific can potentially change the United States’ landscape and eliminate neurology deserts once and for all. It’s time everyone had access to the life-saving research available.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Company announces flagship product name, logo now protected intellectual property rights
• “Securing our trade name is another step forward in the dawning of the Hourglass era,” says CEO
• Grapefruit intends to apply for similar trademark protection when the federal government legalizes cannabis

Grapefruit USA (OTCQB: GPFT), a fully licensed, California-based cannabis company, has secured California Trademark protection for its patented disruptive Hourglass(TM) THC/Cannabinoid time-release delivery cream. The trademark protection means that the Hourglass name and logo are now protected intellectual property rights of Grapefruit and no other cannabis companies can use them. “Obtaining our California Trademark protection for Hourglass is pivotal for us to protect our intellectual property rights and good will with respect to Grapefruit’s Hourglass line of products,” said Grapefruit CEO Bradley J. Yourist. “It is only fitting that Grapefruit has exclusive rights to the Hourglass name and logo since Grapefruit has an exclusive license for use of the patented technology upon which the Hourglass time release delivery cream is based and is the only enterprise on earth with the technical know-how to manufacture the Hourglass delivery cream for the regulated cannabis market. That symmetry is exquisite. Securing our trade name is another step forward in the dawning of the Hourglass era. Hourglass products may only be obtained from Grapefruit and its authorized agents.” In addition to precluding other companies from using the name, the trademark protection gives Grapefruit common law, first-in-time, trademark protection to Hourglass. The company intends to apply for similar trademark protection when the federal government legalizes cannabis, a move that many industry experts feel is imminent, perhaps even this year. “We previously secured California trademark and service mark protections for the Grapefruit corporate name and other product lines, Sugar Stoned and Rainbow Dreams,” Yourist continued. “Currently, the federal government does not allow cannabis companies to obtain federal trademark protection of its intellectual property. We, however, have long understood our operational environment and moved to protect our intellectual property rights at the state level because such state-level registration provides Grapefruit with a significant level of protection on a national basis via common law first-in-time use of our product names. We believe that protection of our intellectual property rights is important to enhance and protect Grapefruit’s value for its shareholders.” Hourglass products are manufactured exclusively at Grapefruit’s Coachillin facility by highly trained Grapefruit personnel and are available to the public only through Grapefruit authorized retailers. Grapefruit has packed the entire cannabis plant into its patented cream to provide users with a wide array of cannabinoids and THC to consistently deliver the desired synergistic entourage effects. To find out more about the company and its game-changing Hourglass time release THC+ Cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Biden calls for 100-day review of strategic supply chains
• Already leading uranium/vanadium producer, UUUU has made significant strides in REE space in 2021
• Energy Fuels on schedule to produce intermediate rare earth product in 2021

In the midst of President Joe Biden’s 100-day review of U.S. strategic supply chains (https://ibn.fm/jc5jW), companies around the country, including Energy Fuels (NYSE American: UUUU) (TSX: EFR), are watching closely for the results. Last year, Energy Fuels, the country’s largest producer of uranium and the leading conventional producer of vanadium, announced plans to enter the rare earth elements (“REE”) space. Just under a year later, the company is about to begin commercial production of an intermediate rare earth product at its facility in Utah. This product contains excellent distributions of the rare earths needed for electric vehicles (“EVs”), renewable energy systems, batteries, technology, and military and defense applications. The supply chain review is intended to boost manufacturing jobs by strengthening U.S. supply chains for advanced batteries, pharmaceuticals, critical minerals and semiconductors; the review will also examine the nation’s reliance on imports of these goods — a potential national security and economic risk that the Biden administration hopes to address. “These are the kinds of common sense solutions that all Americans can get behind,” Biden said, discussing the review. “It’s about resilience, identifying possible points of vulnerabilities in our supply chains and making sure we have the backup alternatives or workarounds in place.” The review appeared to be distinctly bipartisan; an AP article reported that Biden met with Republican and Democratic lawmakers at the Oval Office before signing the order. “This is a critical area where Republicans and Democrats agreed — it was one of the best meetings I think we’ve had so far and we’ve only been here about five weeks,” Biden said. “It was like the old days. People were actually on the same page.” Energy Fuels has a keen interest in the outcome of the analysis. Last year, the company announced its interest in entering the REE market as a complement to its core uranium and recycling businesses. Since that announcement, the company has emerged as a major player in the commercial rare earth business. Its initial goal was to enter the commercial REE business in H1 2021, working to supply up to 50% of U.S. rare earth demand contained in a mixed REE carbonate over the next few years. The company is expected to soon begin processing its first monazite ore at its White Mesa Mill in Blanding, Utah, and producing a marketable mixed rare earth element carbonate. If successful Energy Fuels will be producing a rare earth product at a stage more advanced than any other U.S. company. This work represents a crucial step toward re-establishing a fully integrated U.S. rare earth element supply chain. In addition, the company has plans to install REE separation and additional downstream capabilities over the next few years. These plans can be implemented within the company’s existing infrastructure (https://ibn.fm/gSXQP). With its expansion into the growing REE market, strong balance sheet, diverse business opportunities, and all debt paid off last year, the company is leveraging a robust business model that allows it to be well positioned to capitalize on the increasing momentum for the REE space. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Shark Tank survivor James Martin sells Copa Di Vino to SBEV, 13,000 new retail locations in acquisition agreement
• Copa Di Vino is ready-to-drink portable wine glass that doesn’t require bottle or corkscrew
• After Shark Tank appearance, Copa Di Vino generated tens of millions of dollars in revenue
• SBEV develops, accelerates, grows pre-existing brands for profitable exit events

After turning down multiple offers on Shark Tank years ago, James Martin, the show’s “most infamous entrepreneur” and founder of Copa Di Vino, ultimately sold his business to Splash Beverage Group (OTCQB: SBEV), a portfolio company of successful beverage brands (https://ibn.fm/CKk7L). SBEV management is confident it can accelerate the Copa Di Vino brand for massive expansion through its top-tier production, supply chain and global distribution capabilities. “The acquisition adds a remarkable revenue stream to Splash’s bottom line and includes Copa Di Vino’s proprietary packaging technology, an innovation suitable for a number of applications across the Company’s growing portfolio of beverage brands and industry solutions,” said SBEV CEO Robert Nistico. After turning down the sharks – not once, but twice – Copa Di Vino went on to generate tens of millions of dollars in revenue. Fueled by Martin’s passion for wine and technological expertise, the brand features innovative packaging that allows winemakers to ship their products in a single-serve format, allowing connoisseurs to consume and carry wine in a convenient, portable design. “That’s never been done with wine before, and I grant him that was a good move,” said Kevin O’Leary, renowned venture capitalist and star of Shark Tank. Packaged wine in sizes below 500ml are gaining rapid traction across the United States, according to IWSR Drinks Market Analysis (https://ibn.fm/5qxI8). Single-serve adult beverages like Copa Di Vino’s “wine in a glass” are growing in popularity for consumption at outdoor events due to their easy portability and non-breakable nature—especially in light of COVID-19’s accelerated impact on carry-out services and outdoor seating availability at eateries. SBEV’s acquisition of Copa Di Vino is leveraging this trend through new distribution channels that include the Anheuser-Busch Network, 13,000 retail locations across various chains, and new e-commerce outlets. “As the large venue segment reopens for sports, concerts and other live audience events, we expect to capture meaningful sales volume as this packaging is a perfect fit for stadiums, theaters and other large venues, and the patented packaging technology is not limited to wine,” said Nistico. “We anticipate making use of the versatile utility here in a very big way as market opportunities continue to emerge and resurface.” Among SBEV’s current portfolio are three other unique brands that include TapouT Performance – a natural isotonic hydration & recovery sports drink, Salt Naturally Flavored Tequila, and Pulpoloco Sangria – a premium crafted sangria in an eco-friendly biodegradable catocan. Led by an expert management team with a track record of success, SBEV’s strategy is to rapidly develop and accelerate pre-existing brands that can be profitably exited for cash events. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• Every product features three parts: dosing device, formulation accessory and mobile app
• HIPPA-compliant cloud collects data along each step that is essential in tailoring personalized treatment plan
• RYAH offers multi-product ecosystem that provides remote-health solutions in patient treatment

RYAH Group a digital health-care analytics and technology company, has developed an ecosystem of IoT products in its mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments (https://ibn.fm/1wvz4). Every product features three parts: the device, the formulation accessory (QR labeled product) and the mobile application. These parts work together to control the dosing while also capturing important data that can lead to breakthroughs in plant-based medicine. Every RYAH dose-measuring product has an innovative dose-control solution. Using QR-labeled products, patients can track what they use and evaluate what dosing parameters work best for each product. The QR labeling allows for advanced session tracking and journaling and is designed to ensure safety. Patients can then control and rate the effectiveness of each session on RYAH’s mobile app. This allows the user to tweak future doses to provide more optimal results. The HIPPA-compliant cloud collects data along each step of the ecosystem that is essential in tailoring a personalized treatment plan moving forward. The suite of products also provides critical information for future treatment of patients with various medical conditions. The company releases a monthly in-depth analytical report sharing publicly identified trends and how dosing affects consumer outcomes. RYAH ecosystem includes a range of IoT devices, including Smart Patch, Smart Inhaler and the upcoming Smart Pen, as well as RYAH MD remote health platform. The Smart Patch allows users to access on-demand relief and schedule doses based on when their symptoms are the most severe. After using the QR labeled product, the mobile app’s user records how well the patch worked. Users can then review stats and create an optimized schedule for later use. It creates an organized record of what patches worked best. RYAH’s Smart Inhaler allows users to control how much is inhaled, ensuring consistent and predictable results. Temperature and dosage can be controlled, and then the effects can be recorded in the mobile app. Statistics can be reviewed, and dosing can be altered accordingly for future uses. The Smart Pen allows for oral consumption and can uniquely dose up to three different liquid formulations for a highly personalized effect. The dose can be added to a drink or directly into the mouth. The app is then used to record the effects of the dose for review to make any changes for future dosing. RYAH MD is a service that allows clinicians to remotely monitor and control patients’ dosing regimens with the before-mentioned dose-measuring products. It provides necessary information that doctors can analyze to learn how different dosing variables affect outcomes. RYAH MD allows the doctor to recommend parameters on the smart devices for dosing, review the information in real-time, and make changes remotely to the doses delivered. It will enable doctors to monitor their patients and ensure that they are following the recommended procedures. RYAH Cloud captures all of the structured and unstructured data from the dosing products and the mobile apps and analyzes the information. This allows doctors and clinics to develop more personalized therapies that can reshape our medical future. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• The United States continues to experience acts of anger and hatred stemming from sharp partisan divides that are often ideological and historical in nature
• California-based Knightscope has been developing a line of autonomous security robots (“ASRs”) designed to monitor activities at clients’ properties and report concerns to security personnel
• The robots come in one stationary and two mobile models capable of using AI to monitor, record and transmit data stemming from features including facial recognition, heat sensors, audio and data transmissions and video in low-light circumstances
• Knightscope’s founders have developed a mission of making the United States the safest country in the world through client contracts for the ASRs

Recent years have seen a growing polarization of societal groups across the planet, driven not only by political forces but now also by frustrations over health sciences and reawakened discord in race relations that sometimes lead to violent interactions between people on ideological grounds rather than the physical needs that so commonly spawn crime. It’s a trend that has also awakened a call for better vigilance from Autonomous security robot (“ASR”) developer Knightscope. “Americans are by and large entrenched in their political and cultural tribes, and virtually nothing can budge them out of their partisan voting lanes,” Time magazine intoned following last year’s elections in the United States. “America remains deeply polarized, few voters are truly persuadable, and angry gridlock will likely dominate Washington D.C.” (https://ibn.fm/CNLuU). “Sovereign power of the people does not mean that mobs and other groups of people can intervene to intimidate or force government action,” a senior leader in The Church of Jesus Christ of Latter-day Saints told frequently partisan U.S. members in an appeal for unity during a religious broadcast earlier this month. “There are many political issues, and no party, platform or individual candidate can satisfy all personal preferences. Each citizen must therefore decide which issues are most important to him or her at any particular time … It may require changing party support or candidate choices, even from election to election” (https://ibn.fm/JQBuw). Last year’s political protests and rioting over police powers gave way to the storming of the U.S. Capitol by malcontents in January while Congress was in session, and then the mass shootings in March that marked the first such incidents to take place since the pandemic brought many aspects of normal daily interaction to a standstill. And the discord is further evident in medical technology pioneer Moderna’s recent declaration that it believed it was necessary to spend more than $1 million on security for its CEO and other company executives as it was in the process of rolling out one of the leading vaccines to combat the pandemic. “In response to the increased profile of our company and our executives as we pursued the development of a vaccine against COVID-19, in 2020 the company authorized the provision of personal and home security services to certain” executives, the company’s most recent proxy filing states, as reported by Trade magazine Security (https://ibn.fm/dddEb). Knightscope founder and CEO William Santana Li, a New York City native, said he became “profoundly pissed off” by the terrorist attacks on America’s infrastructure back in 2001, and made it his personal mission to help the country’s private entities and their government become more secure. The company has rolled out three models of ASRs so far — a stationary, in-building K1 robot that is able to monitor for a variety of high-tech data points, ranging from a 360-degree video feed’s facial recognition prowess to data broadcasts and thermal fluctuations. The company’s K3 model in an indoor mobile unit designed to patrol hallways and office space as desired by clients, while the K5 unit takes Knightscope’s ASR sentry offering outside to patrol the grounds of the clients’ property. Testimonials about the K5’s performance at a Las Vegas apartment complex include a police department report that the property went from being in the top three for 911 calls in the area to no longer being in the top 10. (even though the ASRs are simply high-tech non-defensive, unarmed monitors capable of observing, recording and communicating requested information via the Knightscope Security Operations Center). https://ibn.fm/6st3U. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• HempFusion Wellness Inc. has been eying the Asian market for some time, as indicated in its latest operational update to investors
• With the recent announcement that it had received conditional approval to launch its CBD products on Tmall Global, HempFusion looks set to meet its other expansion targets
• The announcement follows a similar move by its wholly owned subsidiary, Probulin Probiotics, and confirms HempFusion’s reliance on Probulin as a gateway to international markets

HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) recently announced it had received conditional approval to launch its CBD products on Tmall Global, the world’s largest cross-border online marketplace. This latest move by the Denver-based leading health and wellness CBD company is backed by a well-thought-out expansion strategy as it follows a similar move by its wholly owned subsidiary, Probulin Probiotics, LLC. In a sponsored Financial Post article earlier this year (https://ibn.fm/9h3BY), Dr. Jason Mitchell, N.D., HempFusion’s co-founder and CEO noted that Probulin serves as a strong foundation for HempFusion to increase its domestic and international distribution. “Probulin’s distribution presence in our key markets gives us a lot of runway opportunities to execute our plan to expand HempFusion into multiple markets that are not readily available to other CBD companies,” he stated. The expansion into the Asian market, which has long been in the company’s sights as indicated in an operational update to investors released April 5 (https://ibn.fm/8cY1q), demonstrates the reliance on its subsidiary very clearly because back in March, HempFusion launched Probulin products on Tmall Global (https://ibn.fm/94DHu). Thus, based on the CEO’s statement, the earlier launch was to pave the way for the entry of the parent company’s products into the Asian market. With the conditional approval given, HempFusion’s OTC topicals, including Acne Relief, Eczema Relief and Sports Pain Relief Creams, Pain Relief and Sports Pain Relief Balms, Pain Relief Gel and Wound Ointment, are expected to launch on Tmall soon, with more products expected to follow. “To be one of the first publicly traded CBD companies on the platform provides us with significant competitive advantages that have the potential to add considerable revenue to our company,” said HempFusion’s Chief Revenue Officer Jon Visser of the approval (https://ibn.fm/S4aFQ). On his part, Dr. Mitchell noted that introducing the company’s products on Tmall, the premier Asian e-commerce platform, had been a major focus in its strategic expansion plan. Notably, Tmall will offer HempFusion the potential of reaching more than 750 million new consumers. “We are now accessing one of the largest online consumer groups in the world with products formulated with approved drug monograph ingredients such as menthol for ailments such as pain. These products have already performed as best in class in select retailers in the United States, and we’re excited to see that follow through in the world’s largest market,” he continued. The latest step is welcome news for a company that experienced a tumultuous 2020, per the operational update. “COVID and continued lack of clarity from the FDA related to official regulatory guidance for CBD used in dietary supplements, foods and beverages has made 2020 a challenging year. However, these challenges have led to strategic changes, establishing the foundation for HempFusion to succeed in 2021 and beyond,” the update reads. The well-thought-out expansion into the Asian market, backed by the positioning of Probulin as a foundational component in its parent company’s expansion drive, is perhaps one of the strategic changes HempFusion has made. In other equally positive news, CBD.U became the first U.S.-based CBD and wellness products company to list directly on the Toronto Stock Exchange (“TSX”) following the completion of a US$17 million initial public offering (“IPO”) in January 2021. Additionally, the company has witnessed an increase in online sales from 6% to 24% in the few months preceding the April 2021 update. The update also noted that HempFusion was targeting international markets such as Latin America, Canada, India, China, and the rest of Europe (besides Ireland and the UK, where the company has already set up shop). With the launch into China already cast in stone, HempFusion looks focused on meeting its expansion targets and generating more revenue as a result. “The future is bright,” the operational update concluded. For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF